I would also add the adjuvant market which was wide open in 2010 got competition when the checkpoints took over this area ...
But of course we are still synergistic ... if it works in this trial (late stage) it stands to reason that we can regain access to the adjuvant setting ... we do NOT have to compete head to head
Konar ... look the dates
INDIANAPOLIS and MAINZ, Germany, May 11, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and BioNTech AG today announced they have entered into a research collaboration to discover novel cancer immunotherapies. The companies will seek to use the power of the body's own immune system to attack cancer cells and create possible new treatment options for cancer patients.
Leveraging the scientific expertise between the two organizations, Lilly and BioNTech will collaborate to identify and validate novel tumor targets and their corresponding T cell receptors (TCRs) in one or more types of cancer. These tumor targets and TCRs may then be engineered and developed into potent and selective cancer therapies.
Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer
GSK announced its decision to stop the MAGRITi trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer (NSCLC) patients, after establishing that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment.
oh look at this ........... same "format as oxford"
French biotech Transgene has ceased the development of a therapeutic cancer vaccine that failed to shrink tumors in patients with lung cancer in a phase II trial.
In the phase II trial, Transgene tested its therapeutic cancer vaccine in combination with chemotherapy and the checkpoint inhibitor drug nivolumab, marketed as Opdivo. The treatment failed to significantly shrink the tumors of 40 patients suffering from non-small cell lung cancer. As a consequence, the company has decided to abandon the vaccine’s development, which was being carried out in collaboration with the big pharma Bristol-Myers Squibb.
The cancer vaccine candidate consists of a modified vaccinia virus that carries the genetic instructions to produce two proteins that boost the response of the immune system against cancer.
This phase II failure is the second major setback for Transgene in the last six months. In August, Transgene decided to abandon the development of a virus-based therapy designed to hunt down and kill cancer cells after interim analyses in a phase III trial concluded that it would be futile.
Transgene’s stock price has sunk by more than 18% on Euronext Paris since the announcement. The company will now focus on developing next-generation oncolytic virus treatments, with one of the most advanced treatments in an ongoing phase I/II trial expected to finish late 2020.
here is another "personalized vaccine" ...
better still why dont we look at ...
What other compounds got a better response than SCIB1 ..... ?
this one ?
Just like SCIB1 ... it has restrictions for use .. HLA you may of seen this with moditope as well ... so the vaccine sCIB1 will work in 45% of patients, in SCIB2 which is a more advanced immunobody this increases to 90% which matches moditope 90% ... so Scancell i suggest are trying to encompass as many HLA types as possible ..
While the details of the clinical picture of the COVID-19 pandemic continue to emerge, there remain substantial unanswered questions regarding the role of individual genetic variability in the immune response against SARS-CoV-2 (51). We hypothesize that individual HLA genotypes may differentially induce the T-cell mediated antiviral response and could potentially alter the course of disease and its transmission. In this study, we performed a comprehensive in silico analysis of viral peptide-major histocompatibility complex (MHC) class I binding affinity across 145 different HLA types for the entire SARS-CoV-2 proteome.
Regarding SARS-CoV-2 CD8+ T cell responses, the pattern of immunodominance found here differed from the literature for other coronaviruses. However, stringent comparisons are not possible, as some earlier studies were not similarly comprehensive and did not utilize the same experimental strategy. The spike protein was a target of human SARS-CoV-2 CD8+ T cell responses, but it is not dominant. SARS-CoV-2 M was just as strongly recognized, and significant reactivity was noted for other antigens, mostly nsp6, ORF3a, and N, which comprised nearly 50% of the total CD8+ T cell response, on average. Thus, these data indicate that candidate COVID-19 vaccines endeavoring to elicit CD8+ T cell responses against the spike protein will be eliciting a relatively narrow CD8+ T cell response compared to the natural CD8+ T cell response observed in mild to moderate COVID-19 disease. An optimal vaccine CD8+ T cell response to SARS-CoV-2 might benefit from additional class I epitopes, such as the ones derived from the M, nsp6, ORF3a, and/or N.
Non Shareholder use "They"
shareholders use "We"
its the small things that let people down ..
another example ...
that SCLP has a really good Portfolio
using SCLP creates distance ...
""so we have a really good portfolio ..."" = part of it .. a shareholder